Taiho Pharmaceutical Company Limited

Hiroyoshi Yamanaka

Shinichi Aoki

Takahiro Asai

Morihiro Mitsuya

Masanori Asai

Masayuki Nakamura

Shigeo Okajima

Kazuhisa Minamiguchi

Takafumi Harada

Suguru Dohi

Kazuaki Shibata

Yoshihiro Urade

Makoto Kitade

Keiko Yamane

Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-&#x3b3; production in vivo. A compound represented by formula (I) [wherein X represents &#x2014;CH&#x2550;CH&#x2014;, &#x2014;NH&#x2014;, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof. 

Pyrrolo[2,3-d]pyrimidine compound or salt thereof

A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof 

Tetrahydropyridopyrimidine compound or salt thereof

A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject 

Azaindole derivative

Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where Rto R, m and n have the same meanings as those defined in the description.

A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier: 

The present invention provides a piperidine compound represented by Formula (I) (wherein X, X, X, A, B and N are as defined in the Description); or a salt thereof.

Growing community of inventors

Moriya, Japan

Hiroyoshi Yamanaka